{"protocolSection":{"identificationModule":{"nctId":"NCT06473259","orgStudyIdInfo":{"id":"A349"},"organization":{"fullName":"Santa Chiara Hospital","class":"OTHER"},"briefTitle":"Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients","officialTitle":"Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Therapy (Alone or in Combination) or Radiotherapy on the Primary Tumor in Combination With Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Multicenter Observational Study of Patients Undergoing Treatment in Clinical Practice in Italian Hospitals","acronym":"ECHOS"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-12-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-05-28","studyFirstSubmitQcDate":"2024-06-24","studyFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-24","lastUpdatePostDateStruct":{"date":"2024-06-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Orazio Caffo","investigatorTitle":"Director","investigatorAffiliation":"Santa Chiara Hospital"},"leadSponsor":{"name":"Santa Chiara Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice"},"conditionsModule":{"conditions":["Prostate Cancer","Hormone Sensitive Prostate Cancer","Metastatic Tumor"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"5 Years","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":3000,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"ADT + docetaxel","description":"mHSPC patients treated with ADT + docetaxel","interventionNames":["Drug: Docetaxel","Drug: Triptorelin"]},{"label":"ADT + ARPI","description":"mHSPC patients treated with ADT + ARPI","interventionNames":["Drug: Apalutamide Oral Tablet","Drug: Enzalutamide Oral Tablet","Drug: Abiraterone acetate tablets","Drug: Triptorelin"]},{"label":"ADT + ARPI + docetaxel","description":"mHSPC patients treated with ADT + docetaxel + ARPI","interventionNames":["Drug: Docetaxel","Drug: Darolutamide Oral Tablet","Drug: Triptorelin"]},{"label":"ADT + radiotherapy on primary tumor","description":"mHSPC patients treated with ADT + radiotherapy on primary tumor","interventionNames":["Radiation: radiotherapy","Drug: Triptorelin"]}],"interventions":[{"type":"DRUG","name":"Docetaxel","description":"6 courses of docetaxel 75 mg/sqm iv","armGroupLabels":["ADT + ARPI + docetaxel","ADT + docetaxel"]},{"type":"DRUG","name":"Apalutamide Oral Tablet","description":"240 mg /daily orally","armGroupLabels":["ADT + ARPI"]},{"type":"DRUG","name":"Enzalutamide Oral Tablet","description":"600 mg /daily orally","armGroupLabels":["ADT + ARPI"]},{"type":"DRUG","name":"Abiraterone acetate tablets","description":"1000 mg /daily orally","armGroupLabels":["ADT + ARPI"]},{"type":"DRUG","name":"Darolutamide Oral Tablet","description":"600 mg/daily orally","armGroupLabels":["ADT + ARPI + docetaxel"]},{"type":"RADIATION","name":"radiotherapy","description":"radical radiotherapy on primary tumor","armGroupLabels":["ADT + radiotherapy on primary tumor"]},{"type":"DRUG","name":"Triptorelin","description":"3,75 mg im/4 w","armGroupLabels":["ADT + ARPI","ADT + ARPI + docetaxel","ADT + docetaxel","ADT + radiotherapy on primary tumor"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"progression free survival","description":"the projected rate over the time of patients without progressive disease","timeFrame":"From date of treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months"}],"secondaryOutcomes":[{"measure":"overall survival","description":"the projected rate over the time of alive patients","timeFrame":"From date of treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months"}],"otherOutcomes":[{"measure":"rate of patients with an objective response","description":"rate of patients who experienced a reduction of at least 30% of measurable lesions","timeFrame":"through study completion, an average of 2 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. histologically confirmed diagnosis of adenocarcinoma of the prostate, metastatic, not undergoing previous treatment (except hormone therapy initiated no more than 4-6 months prior to docetaxel) for metastatic disease\n2. treatment with docetaxel, ARPI (alone or in combination) or with radiation therapy on the primary tumor in combination with ADT within normal clinical practice or expanded access programs initiated between January 2015 and December 2027.\n3. availability of inpatient and/or outpatient medical records for clinical data collection\n\nExclusion Criteria:\n\n1. histological diagnosis other than adenocarcinoma\n2. patients who have received multiple lines of ADT for mCSPC\n3. patients who have received docetaxel or ARTA for metastatic castration-resistant disease","sex":"MALE","stdAges":["CHILD","ADULT","OLDER_ADULT"],"studyPopulation":"All patients with mCSPC who initiated treatment with docetaxel, ARPI (alone or in combination) or with radiotherapy on the primary tumor in addition to ADT within clinical practice or expanded access programs in Italian hospitals from January 2015 to December 2027 will be studied.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Orazio Caffo, MD","role":"CONTACT","phone":"+390461904416","email":"orazio.caffo@apss.tn.it"}],"locations":[{"facility":"Azienda Ospedaliera San Luigi","status":"RECRUITING","city":"Orbassano","state":"Torino","zip":"10043","country":"Italy","contacts":[{"name":"Consuelo Buttigliero, MD, PhD","role":"CONTACT","phone":"+390116705492","email":"consuelo.buttigliero@unito.it"},{"name":"Consuelo Buttigliero, MD, PhD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Istituto Oncologico Veneto","status":"RECRUITING","city":"Padova","zip":"35128","country":"Italy","contacts":[{"name":"Umberto Basso, MD","role":"CONTACT","phone":"+39-049-8215953","email":"umberto.basso@iov.veneto.it"},{"name":"Basso Umberto","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"Santa Chiara Hospital","status":"RECRUITING","city":"Trento","zip":"38122","country":"Italy","contacts":[{"name":"Orazio Caffo, MD","role":"CONTACT","phone":"+39 046190212","email":"orazio.caffo@apss.tn.it"},{"name":"Orazio Caffo","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":46.06787,"lon":11.12108}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000011471","term":"Prostatic Neoplasms"},{"id":"D000009362","term":"Neoplasm Metastasis"},{"id":"D000006967","term":"Hypersensitivity"}],"ancestors":[{"id":"D000005834","term":"Genital Neoplasms, Male"},{"id":"D000014565","term":"Urogenital Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000005832","term":"Genital Diseases, Male"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000011469","term":"Prostatic Diseases"},{"id":"D000052801","term":"Male Urogenital Diseases"},{"id":"D000007154","term":"Immune System Diseases"},{"id":"D000009385","term":"Neoplastic Processes"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M14335","name":"Prostatic Neoplasms","asFound":"Prostate Cancer","relevance":"HIGH"},{"id":"M10018","name":"Hypersensitivity","asFound":"Sensitive","relevance":"HIGH"},{"id":"M12307","name":"Neoplasm Metastasis","asFound":"Metastatic Tumors","relevance":"HIGH"},{"id":"M8946","name":"Genital Neoplasms, Male","relevance":"LOW"},{"id":"M17315","name":"Urogenital Neoplasms","relevance":"LOW"},{"id":"M2876","name":"Genital Diseases","relevance":"LOW"},{"id":"M8944","name":"Genital Diseases, Male","relevance":"LOW"},{"id":"M2875","name":"Urogenital Diseases","relevance":"LOW"},{"id":"M14333","name":"Prostatic Diseases","relevance":"LOW"},{"id":"M27095","name":"Male Urogenital Diseases","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"M12330","name":"Neoplastic Processes","relevance":"LOW"},{"id":"T3215","name":"Kennedy Disease","asFound":"Androgen Receptor","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077143","term":"Docetaxel"},{"id":"D000069501","term":"Abiraterone Acetate"},{"id":"D000017329","term":"Triptorelin Pamoate"}],"ancestors":[{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000050257","term":"Tubulin Modulators"},{"id":"D000050256","term":"Antimitotic Agents"},{"id":"D000050258","term":"Mitosis Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000065088","term":"Steroid Synthesis Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000006727","term":"Hormone Antagonists"},{"id":"D000006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065607","term":"Cytochrome P-450 Enzyme Inhibitors"},{"id":"D000008186","term":"Luteolytic Agents"},{"id":"D000003271","term":"Contraceptive Agents, Female"},{"id":"D000003270","term":"Contraceptive Agents"},{"id":"D000012102","term":"Reproductive Control Agents"},{"id":"D000080066","term":"Contraceptive Agents, Hormonal"},{"id":"D000018931","term":"Antineoplastic Agents, Hormonal"}],"browseLeaves":[{"id":"M19618","name":"Triptorelin Pamoate","asFound":"Liver Transplantation","relevance":"HIGH"},{"id":"M1668","name":"Docetaxel","asFound":"Physical","relevance":"HIGH"},{"id":"M451","name":"Abiraterone Acetate","asFound":"Pharmacological","relevance":"HIGH"},{"id":"M9789","name":"Hormones","relevance":"LOW"},{"id":"M4059","name":"Androgens","relevance":"LOW"},{"id":"M26197","name":"Tubulin Modulators","relevance":"LOW"},{"id":"M26196","name":"Antimitotic Agents","relevance":"LOW"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M9788","name":"Hormone Antagonists","relevance":"LOW"},{"id":"M30537","name":"Cytochrome P-450 Enzyme Inhibitors","relevance":"LOW"},{"id":"M6494","name":"Contraceptive Agents","relevance":"LOW"},{"id":"M6495","name":"Contraceptive Agents, Female","relevance":"LOW"},{"id":"M2116","name":"Contraceptive Agents, Hormonal","relevance":"LOW"},{"id":"M20966","name":"Antineoplastic Agents, Hormonal","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"Repr","name":"Reproductive Control Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}